-
Target Selection & Mechanisms of Action
-
Target Selection & Mechanisms of Action
Recent advances in transient gene expression and AI-assisted antibody engineering have enabled rapid
...
-
ADC Cytotoxic Payload
-
ADC Linker Design & Conjugation Technologies
-
ADC Linker Design & Conjugation Technologies
-
Formats & Scaffolds
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Track antibody and ADC programs by leveraging CDD Vault’s chemically aware macromolecule capabilitie
...
-
ADC Cytotoxic Payload
How can we effectively identify the optimal payload–linker combinations to enhance the efficacy and
...
-
ADC Cytotoxic Payload
At what stage in lead optimization does AI create the most value - affinity maturation, developabili
...
-
Target Selection & Mechanisms of Action
-
Target Selection & Mechanisms of Action
How can we address the challenge of candidate antigens being expressed in both diseased and healthy
...
-
ADC Cytotoxic Payload
What cellular pathways are responsible for the altered intracellular trafficking or limited lysosoma
...
-
ADC Linker Design & Conjugation Technologies
-
ADC Linker Design & Conjugation Technologies
How can linker design balance systemic stability, efficient intracellular cleavage, and overall toxi
...
-
Formats & Scaffolds
How can generative models compress traditional screening funnels from billions of candidates to doze
...
-
ADC Linker Design & Conjugation Technologies
-
ADC Linker Design & Conjugation Technologies
-
Target Selection & Mechanisms of Action
-
Target Selection & Mechanisms of Action
Where does the therapeutic antibody — or the antibody component of an ADC — localize within complex
...
-
Bi/Multispecifics
Optimizing protein therapeutics for clinical success: How can incorporating developability assessmen
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
How can we obtain sufficient high-quality antibody–antigen structural and binding data to prevent sp
...
-
Formats & Scaffolds
What is the minimum of sdAb architecture we have to try? How to efficiently link the screening of bi
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Navigating vast sequence space: How can teams efficiently explore enormous antibody repertoires to p
...
-
Target Selection & Mechanisms of Action
-
Target Selection & Mechanisms of Action
Why is tumor microenvironment (TME) reprogramming emerging as a critical frontier beyond checkpoint
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
The PioneerTM Antibody Discovery Platform is Bio-Rad’s biotherapeutic antibody generation service, c
...
-
Bi/Multispecifics
The performance of multispecific antibody therapeutics is largely determined at the discovery stage.
...
-
Formats & Scaffolds
How do current VH Tg mouse and/or synthetic library platforms compare to traditional llama immunizat
...
-
Bi/Multispecifics
Why is reliance on the endogenous immune recognition system (TCE + MHC + antigen) insufficient for e
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
How are new manufacturing methods changing yield requirements? How are formulation options changing
...
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Bio-Rad’s Pioneer Antibody Discovery Platform includes one of the largest Fab libraries ever made, c
...
-
Bi/Multispecifics
How can cell-surface target degraders be engineered to achieve efficient internalization and sustain
...
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Drinks-Canape Reception
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Afternoon Refreshments
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
1-2-1 Meetings / Networking Break
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
1-2-1 Meetings / Networking Break
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Networking Lunch
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Morning Refreshments
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
1-2-1 Meetings / Networking Break
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
1-2-1 Meetings / Networking Break
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
With the increasing ease of isolating monoclonal antibodies (MAbs) comes the growing challenge of en
...
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Registration